High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma

Hematological Oncology

Volumn 33, Issue 2, 2015, Pages 110-112

  Marchesi, Francesco ^a,c   Cirillo, Mariangela ^a   Bianchi, Antonella ^a   Gately, Michela ^a   Olimpieri, Odoardo M ^a   Cerchiara, Elisabetta ^a   Renzi, Daniela ^a,d   Micera, Alessandra ^b   Balzamino, Bjorn O ^b   Bonini, Stefano ^a   Onetti Muda, Andrea ^a   Avvisati, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d S EUGENIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CD163 ANTIGEN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN FC FRAGMENT; KI 67 ANTIGEN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY;

ALBUMIN BLOOD LEVEL; CELL DENSITY; CELL INFILTRATION; CONFOCAL MICROSCOPY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LETTER; LIGHT; MACROPHAGE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REMISSION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; ANALOGS AND DERIVATIVES; CELL COUNT; CHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL COUNT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MACROPHAGES; POLYETHYLENE GLYCOLS; PREDNISONE; PROGNOSIS; RECEPTORS, CELL SURFACE; RITUXIMAB; TREATMENT OUTCOME; VINCRISTINE;

EID: 84930923761     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2142     Document Type: Letter

References (10)

1. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. New Engl J Med 2010; 362: 875-885.
2. Hasselblom S, Hansson U, Sigurdardottir M, et al. Expression of CD68 + tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 2008; 58: 529-532.
3. Wada N, Zaki MAA, Hori Y, et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 2012; 60: 313-319.
4. Cai QC, Liao H, Lin SX, et al. High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol 2011; 29: 2317-2322.
5. Nam SJ, Go H, Paik JH, et al. An increase of M2 macrophages predicts poor prognosis in diffuse large B-cell lymphoma patients treated wit Rituximab-CHOP. Leuk Lymphoma 2014; DOI: 10.3109/10428194.2013.879713
6. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
7. Wang X, Deavers M, Patenia R, et al. Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease. J Translational Med 2006; 4: 30.
8. Pettersen JS, Fuentes-Duculan J, Suárez-Fariñas M, et al. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol 2011; 131: 1322-1330.
9. Edin S, Wikberg ML, Dahlin AM, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS ONE 2012; 7: e47045.
10. Ma J, Liu L, Che G, et al. The M1 form of tumor associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010; 10: 112.